Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

@inproceedings{Karachaliou2018InterferonGA,
  title={Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients},
  author={Niki Karachaliou and M. Gonzalez-Cao and Guillermo J Crespo and Ana Drozdowskyj and Erika Aldeguer and Ana Gim{\'e}nez-Capit{\'a}n and Cristina Teixid{\'o} and Miguel A. Molina-Vila and Santiago Viteri and Mar{\'i}a de Los Llanos Gil and Salvador Mart{\'i}n Algarra and Elisabeth P{\'e}rez-Ruiz and I. M{\'a}rquez-Rodas and Delvys Rodr{\'i}guez-Abreu and Remedios Blanco and Teresa Pu{\'e}rtolas and Mar{\'i}a Angeles Lou Royo and Rafael Rosell},
  booktitle={Therapeutic advances in medical oncology},
  year={2018}
}
Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or can be upregulated via interferon gamma (IFN-γ). We have explored whether the expression of IFNG, the gene encoding IFN-γ, is associated with clinical response to the immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients. The role of inflammation-associated transcription factors STAT3, IKBKE, STAT1 and other associated genes has also been examined. Methods: Total RNA from 17… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Melanoma and Vitiligo: In Good Company

VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Beyond PD-L1 Markers for Lung Cancer Immunotherapy

  • International journal of molecular sciences
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 72 REFERENCES

IFNgamma-related mRNA profile predicts clinical response to PD-1 blockade

M Ayers, J Lunceford, M Nebozhyn
  • J Clin Invest
  • 2017
VIEW 1 EXCERPT